MONO6

    Chapter 12-Bone Graft Substitutes: A Regulatory Perspective

    Published: Jan 2003

      Format Pages Price  
    PDF Version (1.2M) 12 $25   ADD TO CART
    Complete Source PDF (32M) 12 $154   ADD TO CART


    Abstract

    FOR MORE THAN 30 YEARS, the orthopedic community, including academic, industrial, and government sectors, has been investigating the use of synthetic-, growth factor-, and cell-based therapies as bone graft substitutes; the ultimate goal of which is to reduce or eliminate the use of autograft in healing bony defects. Synthetic bone graft substitutes, demineralized bone matrix, and bone morphogenetic proteins are legally marketed bone graft substitutes; however, each of these products has a distinct regulatory classification and, as such, requires a different regulatory path for approval prior to marketing.


    Author Information:

    Attawia, M

    Rosier, R

    Gadaleta, SJ
    MITEK Worldwide, a Division of Ethicon Inc., a Johnson & Johnson Company, Norwood, MA


    Paper ID: MONO10069M

    Committee/Subcommittee: F04.23

    DOI: 10.1520/MONO10069M


    CrossRef ASTM International is a member of CrossRef.

    ISBN10: 0-8031-3356-1
    ISBN13: 978-0-8031-3356-3